[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 1984

Shock: Diagnosis and Management

Author Affiliations

From the Departments of Medicine (Drs Houston and Robertson) and Pharmacology (Dr Robertson), the Cooperative Care Center (Dr Houston), and the Medical Intensive Care Unit (Dr Houston), Vanderbilt University, Nashville, Tenn, and the Department of Medicine, Case Western Reserve University, Cleveland (Dr Thompson). Dr Thompson is a Burroughs Wellcome scholar in clinical pharmacology, and Dr Robertson is a teaching and research scholar of the American College of Physicians.

Arch Intern Med. 1984;144(7):1433-1439. doi:10.1001/archinte.1984.00350190125022

• Recent investigations have underscored the great diversity in both the causes and manifestations of clinical shock. The emphasis has shifted toward more specific therapy when that has been possible. Pure vasoconstrictors have assumed a secondary therapeutic role, as volume replacement or expansion has become the initial management of shock. Agents, such as naloxone hydrochloride, corticosteroids, fructose diphosphate, amrinone and milrinone, and nonsteroidal anti-Inflammatory agents, while still experimental, offer improved understanding and management of the shock syndrome.

(Arch Intern Med 1984;144:1433-1439)